SIEMENS HEALTHCARE DIAGNOSTICS, INC. ATELLICA IM ALPHA FETOPROTEIN (AFP); AFP IMMUNOASSAY
|
Back to Search Results |
|
Catalog Number 10995442 |
Device Problem
High Test Results (2457)
|
Patient Problem
No Clinical Signs, Symptoms or Conditions (4582)
|
Event Date 08/13/2022 |
Event Type
malfunction
|
Manufacturer Narrative
|
An outside of the us customer (ous) reported an observation of elevated atellica im alpha fetoprotein (afp) patient results which were discordant relative to repeat testing.The intended use according to the instructions for use (ifu) is as follows: "the atellica® im alpha fetoprotein (afp) assay is for in vitro diagnostic use in the quantitative determination of alpha-fetoprotein using the atellica® im analyzer for: human serum, plasma (edta and lithium heparin), and amniotic fluid from specimens obtained at 15-20 weeks gestation, as an aid in detecting open neural tube defects (ntds) when used in conjunction with ultrasonography and amniography testing human serum and plasma (edta and lithium heparin), as an aid in managing non-seminomatous testicular cancer when used in conjunction with physical examination, histology/pathology, and other clinical evaluation procedures." the ifu indicates the following: "warning use afp results only as part of the overall clinical evaluation of a patient.Do not use afp results as the only criterion for diagnosis." "the atellica im afp assay is not a screening test for cancer and must never be used as such.Afp testing is a safe and effective supplement to patient care when used as part of the overall management strategy for patients undergoing treatment for non-seminomatous testicular cancer or for patients being monitored after therapy is complete." the interpretation of results section in the ifu states: "results of this assay should always be interpreted in conjunction with the patient's medical history, clinical presentation, and other findings." siemens is investigating.
|
|
Event Description
|
The customer reported an observation of elevated atellica im alpha fetoprotein (afp) patient results which were discordant relative to repeat testing.The patient samples were re-tested on another atellica im instrument due to an observed shift in moving average for afp results.Lower results were obtained upon repeat testing, and accepted as correct.There are no allegations of patient intervention or adverse health consequences due to the discordant afp results.
|
|
Manufacturer Narrative
|
Siemens filed mdr 1219913-2022-00309 initial report on 2022-09-20.Additional information 2022-09-21: device was not serviced by a third party; section d8 of this report was updated accordingly.Additional information - 2022-10-18: siemens has concluded the investigation for an outside of the united states (ous) customer for an observation of elevated atellica im alpha fetoprotein (afp) results which were discordant relative to repeat testing.The patient samples were run on reagent pack id (b)(6) (lot 254).Initial results were reported to physician(s) and were questioned and retested, but corrected reports were not issued.The customer noted a positive bias in the moving average and initial patient results.In review of the moving average, it does appear there were two points with >2 standard deviation (sd) for the moving average.It does appear the moving average did come back down on subsequent packs.The quality control (qc) on pack (b)(6) was not significantly different than other packs, however, all patients that were elevated were run on this pack.Patients were not repeated on this specific pack.The customer has not observed any further issues with repeat sample results not matching initial results.Data provided does suggest that the issue may be related to this specific pack, however, the pack was no longer available for testing.Siemens reviewed in-house reagent release data for lot 254 and no imprecision was noted with any of the release testing.Based on the investigation, no product problem was identified.The customer is operational.In section h6, investigation finding and investigation conclusion codes were updated based on the investigation results.
|
|
Search Alerts/Recalls
|
|
|